<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923529</url>
  </required_header>
  <id_info>
    <org_study_id>UW 20-711</org_study_id>
    <nct_id>NCT04923529</nct_id>
  </id_info>
  <brief_title>Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective phase II, single arm mono-institutional study conducted in Queen&#xD;
      Mary Hospital (Hong Kong) assessing the efficacy and safety of TAS 102 in advanced or&#xD;
      metastatic pancreatic cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients must be registered with the Investigator(s) prior to initiation of&#xD;
      treatment. The registration desk will confirm all eligibility criteria and obtain essential&#xD;
      information (including patient number).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>16-week progression-free survival (PFS) rate</measure>
    <time_frame>From the date of screening to radiographically documented progression according to mRECIST 1.1, assessed up to 16 weeks</time_frame>
    <description>The percentage of study population alive and without progression (according to RECIST 1.1) at 16 weeks from the date of informed consent</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>from the date of first study treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 3 years</time_frame>
    <description>PFS is measured from the date of informed consent to radiographically documented progression according to RECIST 1.1 or death from any cause (whichever occurs first). Participants alive and without disease progression or lost to follow up will be censored at the date of their last radiographic assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>from the date of first study treatment to radiographically documented progression according to mRECIST 1.1, assessed up to 3 years</time_frame>
    <description>TTP is measured from the date of informed consent to radiographically documented progression according to RECIST 1.1. Participants death and without disease progression, alive without disease progression, or lost to follow-up will be censored at the date of their last radiographic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>from the date of first study treatment to the date of death from any cause, assessed up to 5 years</time_frame>
    <description>OS is measured from date of informed consent to the date of death from any cause. Participants alive or lost to follow-up will be censored at the date of their last radiographic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>From the date of screening to radiographically documented progression according to mRECIST 1.1, assessed up to 16 weeks</time_frame>
    <description>The percentage of patients with radiologically complete or partial response as determined by the Investigator according to RECIST version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>from the date of screening to radiographically documented progression according to mRECIST 1.1, assessed up to 16 weeks</time_frame>
    <description>The percentage of patients with radiologically complete response, partial response, or stable disease as determined by the Investigators according to RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>from the date of screening to radiographically documented progression according to mRECIST 1.1, assessed up to 16 weeks</time_frame>
    <description>DoR is the time from documentation of tumor response to radiographically documented disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of ECOG performance status</measure>
    <time_frame>from the date of screening to radiographically documented progression according to mRECIST 1.1, an average of 1 years</time_frame>
    <description>Time from date of informed consent until the first date on which ECOG performance status score of 2 or higher was recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of quality of life</measure>
    <time_frame>from the date of screening to radiographically documented progression according to mRECIST 1.1, an average of 3 years</time_frame>
    <description>Decrease from baseline of 10 points or more on the EORTC QLQ-C30 maintained for two consecutive assessments or a decrease of 10 points or more in one assessment followed by death from any cause within 3 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety outcome measures</measure>
    <time_frame>from the date of first study treatment to radiographically documented progression according to mRECIST 1.1 or death from any cause, whichever occurs first, assessed up to 3 years</time_frame>
    <description>Incidence, nature, and severity of adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE 5)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>TAS-102</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single group assignment of TAS-102 in Patients with Advanced, Refractory Pancreatic Adenocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS 102</intervention_name>
    <description>Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5.&#xD;
Days 6 through 7: Recovery Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.&#xD;
Days 13 through 28: Recovery</description>
    <arm_group_label>TAS-102</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histological or cytological confirmed advanced or metastatic pancreatic cancer&#xD;
&#xD;
          2. Measurable disease according to the RECIST criteria (version 1.1) for the evaluation&#xD;
             of measurable disease&#xD;
&#xD;
          3. Documented progression after one or more lines of systemic chemotherapy&#xD;
&#xD;
               1. For the treatment of advanced or metastatic disease&#xD;
&#xD;
               2. Within 6 months after completion of neo-adjuvant therapy or adjuvant therapy&#xD;
&#xD;
          4. Age ≥ 18 years&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance 0-1&#xD;
&#xD;
          6. Written informed consent obtained for clinical trial participation and providing&#xD;
             archival tumor tissue, if available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has disease that is suitable for local therapy administrated with curative intent&#xD;
&#xD;
          2. Has a serious illness or medical condition(s) including, but not limited to the&#xD;
             following:&#xD;
&#xD;
               1. Other concurrently active malignancies excluding malignancies that are disease&#xD;
                  free for more than 5 years or carcinoma-in-situ deemed cured by adequate&#xD;
                  treatment.&#xD;
&#xD;
               2. Known brain metastasis or leptomeningeal metastasis.&#xD;
&#xD;
               3. Active infection (i.e. body temperature ≥38°C due to infection).&#xD;
&#xD;
               4. Ascites, pleural effusion or pericardial fluid requiring drainage in last 4&#xD;
                  weeks.&#xD;
&#xD;
               5. Intestinal obstruction, pulmonary fibrosis, renal failure, liver failure, or&#xD;
                  cerebrovascular disorder.&#xD;
&#xD;
               6. Uncontrolled diabetes.&#xD;
&#xD;
               7. Myocardial infarction within the last 12 months, severe/unstable angina,&#xD;
                  symptomatic congestive heart failure New York Heart Association (NYHA) class III&#xD;
                  or IV&#xD;
&#xD;
               8. Gastrointestinal hemorrhage.&#xD;
&#xD;
               9. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome&#xD;
                  (AIDS)-related illness, or hepatitis B or C.&#xD;
&#xD;
              10. Patients with autoimmune disorders or history of organ transplantation who&#xD;
                  require immunosuppressive therapy.&#xD;
&#xD;
              11. Psychiatric disease that may increase the risk associated with study&#xD;
                  participation or study drug administration, or may interfere with the&#xD;
                  interpretation of study results.&#xD;
&#xD;
          3. Has had treatment with any of the following within the specified time frame prior to&#xD;
             study drug administration:&#xD;
&#xD;
               1. Major surgery within prior 4 weeks.&#xD;
&#xD;
               2. Any systemic therapy within prior 2 weeks.&#xD;
&#xD;
               3. Any radiation within prior 2 weeks.&#xD;
&#xD;
               4. Any investigational agent received within prior 4 weeks.&#xD;
&#xD;
          4. Untreated active hepatitis B or hepatitis C infections.&#xD;
&#xD;
          5. Has received TAS-102.&#xD;
&#xD;
          6. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any&#xD;
             prior therapies (excluding anemia, alopecia, skin pigmentation and platinum-induced&#xD;
             neurotoxicity).&#xD;
&#xD;
          7. Is a pregnant or lactating female.&#xD;
&#xD;
          8. Is inappropriate for entry into this study in the judgment of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chi Leung Chiang, FRCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chi Leung Chiang, FRCR</last_name>
    <phone>+85222554352</phone>
    <email>chiangcl@hku.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Clinical Oncology, HKU</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Leung Chiang, FRCR</last_name>
      <phone>+852 2255 4352</phone>
    </contact>
    <investigator>
      <last_name>Chi Leung Chiang, FRCR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 6, 2021</last_update_submitted>
  <last_update_submitted_qc>June 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

